Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To date, there is no uniform agreement on the most appropriate therapeutic methods for
managing women with uterine adenomyosis and/or adenomyoma who want to preserve their
fertility. Management with hormonal treatment that aims to reduce the proliferation of
endometrial cells is promising, but there is a paucity of well-designed studies to guide
treatment. There is a strong need to develop pharmacological agents that provide an efficient
outcome. Gonadotripn releasing hormone analogues (GnRHa) have been used in several studies,
to produce a constant hypoestrogenic state in a woman with adenomyosis which cause
amenorrhoea, control of pain and uterine shrinkage . Pure antiestrogens, however, may offer
some advantage in the treatment of adenomyosis and trials are required to assess its
usefulness. Leiomyoma and uterine volumes were successfully reduced by use of aromatase
inhibitors (AIs). Assuming aromatase production activity in the adenomyosis lesion, Kimura et
al, used GnRHa and an AI concomitantly for treatment of uterine adenomyosis. This lack of
information stimulated us to run this trial to compare the efficacy of aromatase inhibitor
vs. GnRHa in treating premenopausal women with uterine adenomyosis.